Compare AstraZeneca plc (AZN) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs M&T Bank Corporation — how do they compare? AstraZeneca plc trades at $168.26 (market cap $253.13B), while M&T Bank Corporation trades at $246.78 (market cap $35.42B). The key difference: AstraZeneca plc is far larger — about 7.1× M&T Bank Corporation's market cap, and M&T Bank Corporation pays the higher dividend (2.48%). Which is the better fit depends on your goals.
| AZN | MTB | |
|---|---|---|
Market Cap | $253.13B | $35.42B |
Sector | Health | Financials |
52-Week High | $209.48 | $242.55 |
52-Week Low | $137.44 | $178.63 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
M&T Bank Corporation (MTB) trades at $242.55, up 0.09% today, with a bullish technical signal supported by moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.18 exceeding expectations of $4.02. Revenue grew to $9.63B in 2025, with a net income margin of 29.59%. Recent news highlights Q2 2026 results announcement on July 15, 2026, with expectations of higher net interest income and loan growth.
Outlook remains positive due to strong profitability and dividend stability, but risks include elevated costs and net cash flow volatility. Analyst consensus is mixed with 29% buy ratings, though the price target of $242.72 suggests limited upside from current levels. Investors should weigh solid fundamentals against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
